Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: Results from the second international burden of migraine study (IBMS-II)

Andrew M. Blumenfeld, Lisa M. Bloudek, Werner J. Becker, Dawn C. Buse, Sepideh F. Varon, Gregory A. Maglinte, Teresa K. Wilcox, Ariane K. Kawata, Richard B. Lipton

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Objective Our objective was to characterize patterns of preventive medication use in persons with episodic migraine (EM) and chronic migraine (CM). Background Several classes of medications are used both on- and off-label for the prevention of migraine, including β-blockers (eg, propranolol, timolol), tricyclic antidepressants (eg, amitriptyline), anti-epileptic drugs (eg, topiramate, valproic acid), and neurotoxins (eg, onabotulinumtoxinA). Methods Preventive medication use and reasons for discontinuation were collected in an international, Web-based, cross-sectional survey of adults with migraine during 2010. Descriptive analyses were conducted on demographics and headache-related disability as measured by the Migraine Disability Assessment Scale, stratified by use of preventive medication, and EM or CM. Univariate and multivariate logistic regression models were constructed to assess predictors of preventive medication use. Results One thousand one hundred and sixty-five respondents completed the survey. Only 28.3% of EM and 44.8% of CM respondents were currently using preventive medication; any use of prophylaxis (prior or current) was reported by 43.4% of those with EM and 65.9% with CM. The mean number of prophylactic medications ever used was 2.92 for EM and 3.94 for CM. Antidepressants were used most frequently (EM 60.9%; CM 54.7%), followed by β-blockers (EM 35.4%; CM 36.8%) and anti-epileptics (EM 28.6%; CM 36.3%). Odds of preventive medication use were higher among CM than EM, adjusting for age, gender, race, years of daily headache, and country (odds ratio 2.72; 95% confidence interval 2.15 to 3.57). Greater headache-related disability and older age were also associated with greater odds of ever having used prophylaxis, regardless of headache frequency. Conclusions Less than half the persons with EM and CM were currently using preventive medication for migraine, with treatment rates being higher for CM, as expected. Those with CM tried more medications than those with EM, possibly reflecting higher levels of treatment need.

Original languageEnglish (US)
Pages (from-to)644-655
Number of pages12
JournalHeadache
Volume53
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Migraine Disorders
Headache
Logistic Models

Keywords

  • drug therapy
  • drug utilization
  • migraine disorder
  • migraine headache
  • prophylaxis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine : Results from the second international burden of migraine study (IBMS-II). / Blumenfeld, Andrew M.; Bloudek, Lisa M.; Becker, Werner J.; Buse, Dawn C.; Varon, Sepideh F.; Maglinte, Gregory A.; Wilcox, Teresa K.; Kawata, Ariane K.; Lipton, Richard B.

In: Headache, Vol. 53, No. 4, 04.2013, p. 644-655.

Research output: Contribution to journalArticle

Blumenfeld, Andrew M. ; Bloudek, Lisa M. ; Becker, Werner J. ; Buse, Dawn C. ; Varon, Sepideh F. ; Maglinte, Gregory A. ; Wilcox, Teresa K. ; Kawata, Ariane K. ; Lipton, Richard B. / Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine : Results from the second international burden of migraine study (IBMS-II). In: Headache. 2013 ; Vol. 53, No. 4. pp. 644-655.
@article{d2ff763590c74dd4865762e06e462074,
title = "Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: Results from the second international burden of migraine study (IBMS-II)",
abstract = "Objective Our objective was to characterize patterns of preventive medication use in persons with episodic migraine (EM) and chronic migraine (CM). Background Several classes of medications are used both on- and off-label for the prevention of migraine, including β-blockers (eg, propranolol, timolol), tricyclic antidepressants (eg, amitriptyline), anti-epileptic drugs (eg, topiramate, valproic acid), and neurotoxins (eg, onabotulinumtoxinA). Methods Preventive medication use and reasons for discontinuation were collected in an international, Web-based, cross-sectional survey of adults with migraine during 2010. Descriptive analyses were conducted on demographics and headache-related disability as measured by the Migraine Disability Assessment Scale, stratified by use of preventive medication, and EM or CM. Univariate and multivariate logistic regression models were constructed to assess predictors of preventive medication use. Results One thousand one hundred and sixty-five respondents completed the survey. Only 28.3{\%} of EM and 44.8{\%} of CM respondents were currently using preventive medication; any use of prophylaxis (prior or current) was reported by 43.4{\%} of those with EM and 65.9{\%} with CM. The mean number of prophylactic medications ever used was 2.92 for EM and 3.94 for CM. Antidepressants were used most frequently (EM 60.9{\%}; CM 54.7{\%}), followed by β-blockers (EM 35.4{\%}; CM 36.8{\%}) and anti-epileptics (EM 28.6{\%}; CM 36.3{\%}). Odds of preventive medication use were higher among CM than EM, adjusting for age, gender, race, years of daily headache, and country (odds ratio 2.72; 95{\%} confidence interval 2.15 to 3.57). Greater headache-related disability and older age were also associated with greater odds of ever having used prophylaxis, regardless of headache frequency. Conclusions Less than half the persons with EM and CM were currently using preventive medication for migraine, with treatment rates being higher for CM, as expected. Those with CM tried more medications than those with EM, possibly reflecting higher levels of treatment need.",
keywords = "drug therapy, drug utilization, migraine disorder, migraine headache, prophylaxis",
author = "Blumenfeld, {Andrew M.} and Bloudek, {Lisa M.} and Becker, {Werner J.} and Buse, {Dawn C.} and Varon, {Sepideh F.} and Maglinte, {Gregory A.} and Wilcox, {Teresa K.} and Kawata, {Ariane K.} and Lipton, {Richard B.}",
year = "2013",
month = "4",
doi = "10.1111/head.12055",
language = "English (US)",
volume = "53",
pages = "644--655",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine

T2 - Results from the second international burden of migraine study (IBMS-II)

AU - Blumenfeld, Andrew M.

AU - Bloudek, Lisa M.

AU - Becker, Werner J.

AU - Buse, Dawn C.

AU - Varon, Sepideh F.

AU - Maglinte, Gregory A.

AU - Wilcox, Teresa K.

AU - Kawata, Ariane K.

AU - Lipton, Richard B.

PY - 2013/4

Y1 - 2013/4

N2 - Objective Our objective was to characterize patterns of preventive medication use in persons with episodic migraine (EM) and chronic migraine (CM). Background Several classes of medications are used both on- and off-label for the prevention of migraine, including β-blockers (eg, propranolol, timolol), tricyclic antidepressants (eg, amitriptyline), anti-epileptic drugs (eg, topiramate, valproic acid), and neurotoxins (eg, onabotulinumtoxinA). Methods Preventive medication use and reasons for discontinuation were collected in an international, Web-based, cross-sectional survey of adults with migraine during 2010. Descriptive analyses were conducted on demographics and headache-related disability as measured by the Migraine Disability Assessment Scale, stratified by use of preventive medication, and EM or CM. Univariate and multivariate logistic regression models were constructed to assess predictors of preventive medication use. Results One thousand one hundred and sixty-five respondents completed the survey. Only 28.3% of EM and 44.8% of CM respondents were currently using preventive medication; any use of prophylaxis (prior or current) was reported by 43.4% of those with EM and 65.9% with CM. The mean number of prophylactic medications ever used was 2.92 for EM and 3.94 for CM. Antidepressants were used most frequently (EM 60.9%; CM 54.7%), followed by β-blockers (EM 35.4%; CM 36.8%) and anti-epileptics (EM 28.6%; CM 36.3%). Odds of preventive medication use were higher among CM than EM, adjusting for age, gender, race, years of daily headache, and country (odds ratio 2.72; 95% confidence interval 2.15 to 3.57). Greater headache-related disability and older age were also associated with greater odds of ever having used prophylaxis, regardless of headache frequency. Conclusions Less than half the persons with EM and CM were currently using preventive medication for migraine, with treatment rates being higher for CM, as expected. Those with CM tried more medications than those with EM, possibly reflecting higher levels of treatment need.

AB - Objective Our objective was to characterize patterns of preventive medication use in persons with episodic migraine (EM) and chronic migraine (CM). Background Several classes of medications are used both on- and off-label for the prevention of migraine, including β-blockers (eg, propranolol, timolol), tricyclic antidepressants (eg, amitriptyline), anti-epileptic drugs (eg, topiramate, valproic acid), and neurotoxins (eg, onabotulinumtoxinA). Methods Preventive medication use and reasons for discontinuation were collected in an international, Web-based, cross-sectional survey of adults with migraine during 2010. Descriptive analyses were conducted on demographics and headache-related disability as measured by the Migraine Disability Assessment Scale, stratified by use of preventive medication, and EM or CM. Univariate and multivariate logistic regression models were constructed to assess predictors of preventive medication use. Results One thousand one hundred and sixty-five respondents completed the survey. Only 28.3% of EM and 44.8% of CM respondents were currently using preventive medication; any use of prophylaxis (prior or current) was reported by 43.4% of those with EM and 65.9% with CM. The mean number of prophylactic medications ever used was 2.92 for EM and 3.94 for CM. Antidepressants were used most frequently (EM 60.9%; CM 54.7%), followed by β-blockers (EM 35.4%; CM 36.8%) and anti-epileptics (EM 28.6%; CM 36.3%). Odds of preventive medication use were higher among CM than EM, adjusting for age, gender, race, years of daily headache, and country (odds ratio 2.72; 95% confidence interval 2.15 to 3.57). Greater headache-related disability and older age were also associated with greater odds of ever having used prophylaxis, regardless of headache frequency. Conclusions Less than half the persons with EM and CM were currently using preventive medication for migraine, with treatment rates being higher for CM, as expected. Those with CM tried more medications than those with EM, possibly reflecting higher levels of treatment need.

KW - drug therapy

KW - drug utilization

KW - migraine disorder

KW - migraine headache

KW - prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84876038240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876038240&partnerID=8YFLogxK

U2 - 10.1111/head.12055

DO - 10.1111/head.12055

M3 - Article

C2 - 23458496

AN - SCOPUS:84876038240

VL - 53

SP - 644

EP - 655

JO - Headache

JF - Headache

SN - 0017-8748

IS - 4

ER -